e the Nasdaq decreased a fraction of 1 percent, and the =asdaq Biotech Index dipped 2 percent. PacBio's drop follows a gain of nearly 25 percent in J=ne and was in spite of a reported 89 percent increase in revenues <http://www.genomeweb.com/sequencing/pacific-biosciences-q2-reven=es-climb-89-percent